NLSP - NLS Pharmaceutics Ltd. Price-to-Projected Revenue Ratio

NLS Pharmaceutics Ltd. (NLSP) - corporate logo

NLS Pharmaceutics AG is developing unique treatments for ADHD and narcolepsy, positioning itself for monopoly pricing power. The company is seeking lucrative M&A deals to refresh its clinical base, yet remains vulnerable to regulatory discrepancies between the US and EU. The forward price-to-sales ratio confirms these trends, and shows the current volume of the metric, visualizing market expectations for future sales.

NLS Pharma - NLSP Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

nlspharma.com - analytical breakdowns and key metrics (NLSP)

- market price and analyst price targets:
Price Chart NLS Pharmaceutics|NLSP - Price Target Chart
- market capitalization statistics:
Market Value NLS Pharmaceutics|NLSP - Total Enterprise Value
- book value of equity indicators:
Book Value per Share NLS Pharmaceutics|NLSP - Book Value of Business|Market Cap to Net Assets Ratio nlspharma.com|NLSP - Company Assets
- debt and liquidity data:
Debt to Equity NLS Pharmaceutics AG|NLSP - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity NLS Pharmaceutics|NLSP - Company Debts|Debt to Book Capitalization Ratio NLS Pharmaceutics|NLSP - Long-Term Debt Volume|Company Current Liabilities NLS Pharmaceutics|Quick Liquidity nlspharma.com
- financial results and valuation multiples details:
NLSP - Profit After Tax|Projected Future Earnings NLS Pharmaceutics AG|NLSP - Company Value to Net Income|Forward P/E Multiple NLS Pharmaceutics|NLSP - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharmaceutics|NLSP - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months NLS Pharmaceutics|NLSP - Net earnings per share for the last 12 months|Quarterly EPS earnings growth nlspharma.com|NLSP - Earnings growth in current year|Earnings growth forecast for next year NLS Pharmaceutics AG
- revenue and sales proceeds data:
NLSP - Company Sales|Projected Sales Volume NLS Pharmaceutics|NLSP - Price to Sales|Forward Price-to-Revenue Multiple NLS Pharmaceutics
Summary company analytics:NLSP (NLS Pharma)
Original product of NLS Pharmaceutics

The investment attractiveness of NLS Pharmaceutics AG (NLSP) is based on its expansion into the sleep disorder therapy segment, where capitalization outpaces actual sales. The ratio of market value to projected revenue measures the market's willingness to pay a premium for future capture of the neuropharmacology market; therefore, the current forward P/S level serves as an indicator of price overheating and the risk of correction should asset liquidity decline.

Analysis of competing companies

Price-to-Projected Revenue Ratio Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock Inc.|CNTA: Forward P/S Multiple|Projected Price to Revenue dyne-tx.com DYN|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Rapport Therapeutics Inc RAPP|Price-to-Projected Revenue Ratio Alumis Corp (ALMS)|Zevra Corp - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Contineum Therapeutics, Inc. CTNM|larimartx.com - Price-to-Projected Revenue Ratio|CAPR - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Entrada Therapeutics Inc. TRDA|PTHS (Channel) - Forward Price-to-Revenue Multiple|MediciNova - Forward Price to Sales|Price-to-Projected Revenue Ratio Serina Therapeutics, Inc.|bioxceltherapeutics.com - Future Price to Revenue|Forward P/S Multiple PMN|APUS (apimedsus.com) - Forward Price to Sales|Forward P/S Multiple AEON (AEON Biopharma, Inc.)|Forward P/S Multiple Bionomics Ltd. BNOX|HUGE - Price-to-Projected Revenue Ratio|Forward Price to Sales RETA (reatapharma.com)